• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 13th January 2017

Maynard Matters: A New Publication Covering Alan Maynard’s Contribution to Global Health Economics

Maynard Matters is a new publication edited by Richard Cookson, Maria Goddard and Trevor Sheldon, published by University of York. The publication covers Alan’s contribution to global Health Economics, his thinking about the UK NHS, and his roles as a…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

Maynard Matters is a new publication edited by Richard Cookson, Maria Goddard and Trevor Sheldon, published by University of York. The publication covers Alan’s contribution to global Health Economics, his thinking about the UK NHS, and his roles as a the Founding Director of CHE, the Founding Editor of the journal Health Economics and Chair of York Hospital NHS Foundation Trust.

Maynard Matters is a new publication edited by Richard Cookson, Maria Goddard and Trevor Sheldon, published by University of York, Centre for Health Economics (CHE).

This new publication combines new pieces by leading health economists with extracts from Alan Maynard’s work on efficiency and equity, quality and outcomes, health care financing, markets and competition, workforce, primary care budget holding, pharmaceutical purchasing, and alcohol & drug abuse.

Contributors include OHE’s Research Director Professor Nancy Devlin, OHE Research and Policy Committee member Tony Culyer and past OHE Annual Lecturer Bob Evans. The publication covers Alan’s contribution to global Health Economics, his thinking about the UK NHS, and his role as a the Founding Director of CHE, as the Founding Editor of the journal Health Economics and as Chair of York Hospital NHS Foundation Trust.

One of the papers from Alan in the book, “Performance incentives in general practice”, is his call for GP budget holding at an OHE meeting held in 1985. This paper is part of Health, Education and General Practice (1985), which is available on the OHE website.

In this paper he argues for clearer specification of the basic care package, better information for patients, greater experimentation using pilots of different approaches to running and incentivising GP practices, changes in the doctors contracts, the requirement for all drugs and practices to have proven worth and value for money before being introduced, and community pharmacy to improve GP prescribing as well as for GP fundholding. Each of these ideas has led to a policy implementation, many of which were subsequently shown by researchers to generate benefits.

Alan’s robust approach to using economic thinking to recommend policy to deliver the collective funding of cost-effective health care was also present in his 20th OHE Annual Lecture, which he gave in 2013, five months after release of the Francis Report. This detailed report made 290 recommendations for more regulation. “Sadly”, Maynard notes, “[Francis’s] proposals were not evidenced, not prioritised and not costed”.

UK responses to perceived problems in health care quality, he notes, have produced continuous structural “re-disorganisation” over the past 40 years. These rarely have been evidence based; the disruptions created often were more profound than any improvement.

The alternative to “more regulation (as advocated by lawyers and public inquiries) is better regulation”, according to Alan Maynard. Better regulation, in turn, is based on evidence and economic analysis. Outcomes measurement is at the core of the economic approach to reforming health care. Understanding outcomes, in turn, allows the adoption of effective incentives for change, both financial and non-financial.

Maynard Matters is available for free download as a pdf and as an e-reader here.

A separate CHE web page is also dedicated to stories and messages from friends, colleagues and students.

  • External Publications

Related News

  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
  • News
  • April 2020

Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support

Read more
  • News
  • April 2020

Financing and Scaling Innovation for the COVID Fight: A Closer Look at Demand-Side Incentives for a Vaccine

Read more
  • News
  • February 2020

Unpacking the Black Box of Payer Policy: A Demand-Side Approach for Equitable Uptake of Cost-Effective Health Innovation

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!